243 related articles for article (PubMed ID: 10741292)
1. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
Milano G; McLeod HL
Eur J Cancer; 2000 Jan; 36(1):37-42. PubMed ID: 10741292
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
4. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
5. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Milano G; Chamorey AL
Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
[TBL] [Abstract][Full Text] [Related]
7. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
8. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
Milano G; Etienne MC
Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
[TBL] [Abstract][Full Text] [Related]
9. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
[TBL] [Abstract][Full Text] [Related]
10. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
11. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Nakanishi H; Nakao M; Miki T
Eur J Cancer; 2003 Mar; 39(4):541-7. PubMed ID: 12751387
[TBL] [Abstract][Full Text] [Related]
12. Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?
Collie-Duguid ES; McLeod HL; Cassidy J
Ann Oncol; 2000 Mar; 11(3):255-7. PubMed ID: 10811489
[No Abstract] [Full Text] [Related]
13. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
14. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
[TBL] [Abstract][Full Text] [Related]
15. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Hirano Y; Takayama T; Kageyama S; Ushiyama T; Suzuki K; Fujita K
Eur Urol; 2003 Jan; 43(1):45-51; discussion 51-2. PubMed ID: 12507543
[TBL] [Abstract][Full Text] [Related]
16. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.
Tanaka-Nozaki M; Onda M; Tanaka N; Kato S
Clin Cancer Res; 2001 Sep; 7(9):2783-7. PubMed ID: 11555593
[TBL] [Abstract][Full Text] [Related]
17. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
18. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
Mizutani Y; Wada H; Fukushima M; Yoshida O; Ukimura O; Kawauchi A; Miki T
Eur J Cancer; 2001 Mar; 37(5):569-75. PubMed ID: 11290431
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):21-6; discussion 27. PubMed ID: 11219973
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Takechi T; Okabe H; Fukushima M; Kitajima M
Jpn J Cancer Res; 2000 Jan; 91(1):105-12. PubMed ID: 10744051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
